Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Novel analogs of the Quassinoid family inhibitor for treatment of hematologic malignancies

ABSTRACT: Novel analogs of the Quassinoid family inhibitor for treatment of hematologic malignancies

PROVIDER: PRJNA541225 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9016742.fastq.gz	Fastqsanger.gz
	SRR9016743.fastq.gz	Fastqsanger.gz
	SRR9016744.fastq.gz	Fastqsanger.gz
	SRR9016745.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies specifically target the PI3Kgamma isoform

Project description:Development of novel PI3Ks inhibitors is an important strategy to overcome their resistance and poor tolerability in clinical trials. The quassinoid family member Brusatol shows specific inhibitory activity against hematologic malignancies. However, the mechanism of its anti-cancer activity is unknown. We studied the anti-cancer activity of Brusatol on multiple hematologic malignancies derived cell lines by RNA-Seq, mass spectrometry, biochemical pull-down assays, and CRISPR/Cas9 gene knock-out. We demonstrated that the PI3Kgamma isoform was identified as a direct target of Brusatol, and inhibition was lost on PI3Kgamma deficient cells. Novel synthetic analogs were also developed and tested in vitro and in vivo. They shared superior potency in their ability to inhibit malignant hematologic cell lines, and in a xenograft transplant mouse model. They also had minimal toxicity to normal human cells. These new analogs have enhanced potential for development as a new class of PI3K inhibitors for treatment of hematologic malignancies.

2020-03-06 | MSV000085067 | MassIVE

Activity of EP300/CBP bromodomain inhibitor CCS1477 across diverse hematologic malignancies

Project description:Activity of EP300/CBP bromodomain inhibitor CCS1477 across diverse hematologic malignancies

| PRJNA854913 | ENA

Novel analogs of the Quassinoid family inhibitor for treatment of hematologic malignancies

Project description:Our study is to reveal the molecular mechanism associated with Brusatol-mediated inhibition. RNA-Seq experiment was performed with Brusatol-treated EBV-transformed LCLs to investigate its ability to regulate the cellular transcription program.

2020-05-01 | GSE130728 | GEO

Natural Killer Cell Therapies for Hematologic Malignancies

Project description:Natural Killer Cell Therapies for Hematologic Malignancies

| PRJNA776383 | ENA

Germ cell tumor and associated hematologic malignancies

Project description:Germ cell tumor and associated hematologic malignancies

| PRJNA660497 | ENA

Germ cell tumor and associated hematologic malignancies

Project description:Germ cell tumor and associated hematologic malignancies

| PRJNA660496 | ENA

Natural Killer Cell Therapies for Hematologic Malignancies

Project description:Natural Killer Cell Therapies for Hematologic Malignancies